Dizal (Jiangsu) Pharmaceutical Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Zhang Xiaolin

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	1.8%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Aug 20

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

May 02

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30

AMMINISTRATORE DELEGATO

Zhang Xiaolin (60 yo)

no data

Mandato

CN¥11,727,700

Compensazione

Dr. Zhang Xiaolin Ph.D. is General Manager and Chairman of Dizal (Jiangsu) Pharmaceutical Co., Ltd. and served as its Chief Scientist. Dr. Xiaolin joined the Dizal (Jiangsu) Pharmaceutical Co., Ltd.in 201...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Zhang Xiaolin	GM & Chairman	no data	CN¥11.73m	1.76% CN¥ 348.4m
Guanshan Zhu	Independent Director	4.2yrs	CN¥100.00k	Nessun dato
Simon Dazhong Lu	Director	7.8yrs	Nessun dato	Nessun dato
Rodolphe Peter Andre Grepinet	Director	7.8yrs	Nessun dato	Nessun dato
Jiang Bin	Independent Director	4.2yrs	CN¥100.00k	Nessun dato
Wang Xuegong	Independent Director	4.2yrs	CN¥100.00k	Nessun dato
Zhang Xin	Independent Director	4.2yrs	CN¥100.00k	Nessun dato
Dong Weiwen	Chairman of the Supervisory Board	no data	Nessun dato	Nessun dato
Yuan Sun	Supervisor	no data	Nessun dato	Nessun dato
Xiaojing Kang	Employee Supervisor	2.8yrs	Nessun dato	0.0041% CN¥ 810.1k

4.2yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 688192 sono considerati esperti (durata media dell'incarico 4.2 anni).

Dizal (Jiangsu) Pharmaceutical Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Price target increased by 7.4% to CN¥56.00

Dizal Receives Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Consensus revenue estimates decrease by 12%

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

New minor risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

Consensus EPS estimates fall by 13%

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology

New major risk - Revenue and earnings growth

Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting

Price target increased by 11% to CN¥56.42

Dizal Announces Center for Drug Evaluation Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

Less than half of directors are independent

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC

Dizal Pharmaceutical Announces Pre-Clinical and Clinical Results of Sunvozertinib (DZD9008) Published in Cancer Discovery

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for Dzd4205 for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 (Sunvozertinib) for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media